Interim results presented at EASL from PROVE 1 clinical trial of investigational drug telaprevir in patients with genotype 1 hepatitis C.
Lang
Les
L
D018849:Controlled Clinical Trials as Topic; D015507:Drugs, Investigational; D005060:Europe; D005762:Gastroenterology; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics*; D006526:Hepatitis C / Q000188:drug therapy* / Q000821:virology*; D006801:Humans; D009842:Oligopeptides / Q000009:adverse effects / Q000627:therapeutic use*; D011480:Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood; D012955:Societies, Medical; D016896:Treatment Outcome
D015507:Drugs, Investigational; D009842:Oligopeptides; D011480:Protease Inhibitors; D012367:RNA, Viral; C486464:telaprevir